|
Published by: Takeda Pacific
Published: Jul. 1, 2007 - 131 Pages
Table of Contents
- 1.RNAi Market & Business Models
- Overview of RNA Interference
- Double Stranded RNA (dsRNA)
- Small interfering RNA (siRNA)
- Short Hairpin RNA (shRNA)
- DNA-directed RNAi (ddRNAi)
- MicroRNA (miRNA)
- The RNAi Market & Key Customer Applications
- The WW RNAi Market
- RNAi Tools for Research, Drug Discovery & Development
- As Tools for Basic Research
- As Tools for Drug Discovery
- As Tools for Drug Development
- RNAi-as-Drugs (Therapeutics)
- Competitive Market
- Market Map of Major Players
- Major Players by Focus Segment and Product Strategy
- Research Findings & Analysis
- Market Leaders
- RNAi Moves Upstream on the Drug R&D Path
- Technology Big Picture
- Business Model & Product Development Strategies
- 2.M&A and Alliance Activities
- Analysis of RNAi M&As and Alliances, 2005 to July-2007
- RNAi Alliances and M&As, 2005 to June-2007
- Intellectual Property and Regulatory Approval
- Intellectual Property
- Regulatory Approval
- Findings: Companies to Watch for Future R&D
- RNAi Technology Companies on the Move
- Big Pharma is Involved in RNAi
- 3.Market Forecast and Trends
- The WW RNA Interference (RNAi) Market Size 2006-2011
- WW RNAi Market by Segments
- RNAi Market By WW Regions
- RNAi Market By Application Segments
- RNAi in Basic Research
- RNAi in Drug Discovery
- RNAi in Drug Development
- RNAi Therapeutics
- RNAi Application Segment Market Shares, 2007 & 2011
- RNAi Market By Major Disease Segments
- Cancer
- Infections
- Metabolic
- Eye disease
- CNS
- Respiratory
- Inflammation
- Bone Diseases
- Blood Disease
- Cardiovascular
- Diagnostics, Skin Conditions and Others
- Major Disease Segment Market Shares (%), 2007 & 2011
- RNAi Market By Product Segments
- RNAi Reagents & Related Services
- RNAi Delivery Tools & Devices
- Assay Systems
- Cell Lines & Related
- Discovery Techs, Services & Drugs
- Genomewide RNAi HT/ HC Screening Tools
- RNAi Product Segment Market Shares (%), 2007 & 2011
- Key Trends/ Future Directions
- Big Pharma Starting to Get Involved in RNAi
- Advances Made in Dealing With Off-target Effects
- Growing Knowledge About microRNAs
- Direct Delivery of RNAi-based Drugs
- Systemic Delivery of RNAi Drugs
- RNAi Future Direction Timeline
- 4.Selected Companies Working in RNAi
- Alnylam Pharmaceuticals, Inc.
- Ambion, Inc.
- Avalon Pharmaceuticals, Inc.
- Benitec, Ltd.
- Cenix Bioscience GmbH
- CytRx Corporation
- Dharmacon, Inc.
- Integrated DNA Technologies, Inc. (IDT)
- Intradigm Corporation
- Intronn, Inc.
- Invitrogen Corporation
- Lentigen Corporation
- Mirus Bio Corporation
- Nastech Pharmaceutical Company Inc.
- Open Biosystems
- Opko Health, Inc.
- Panomics, Inc.
- RNAx GmbH
- Sirna Therapeutics, Inc.
- Targeted Genetics Corporation
- 5.Findings and Suggestions
- Review of Findings and Key Trends
- RNAi Technology
- Competitive Landscape
- M&As and Alliances
- Patents
- Market Assessment
- Recommendations to Capture Opportunities
- Products Needed by RNAi Users in R&D
- Future Market Prospects
- 6.Appendix
- RNAi Glossary
- Company Contacts
- About Takeda Pacific
- About the Authors
- List of Tables
- Table 1. Diseases Targeted by Direct Delivery of RNAi Drugs
- Table 2. Diseases Targeted by Systemic Delivery of RNAi Drugs
- Table 3. Major Players in the RNAi Market
- Table 4. Major Players by Focus Segment and Product Strategy
- Table 5. Summary of RNAi M&As and Alliances, 2005 to July-2007
- Table 6. M&As and Alliances, Jan-July/ 2007
- Table 7. M&As and Alliances, 2006
- Table 8. M&As and Alliances, 2005
- Table 9. RNAi Related Patent Applications (US), 2002-1H2007
- Table 10. Key Patents for RNAi Reagents and Drugs
- Table 11. RNAi Therapeutics In /(or Near) Clinical Trials
- Table 12. Top RNAi Alliance Players: RNAi Technology Companies
- Table 13. Top RNAi Alliance Players: Big Pharmas
- Table 14. WW RNAi Market Size By Total Revenues ($M), 2006-2011
- Table 15. WW RNAi Market By WW Regions and Revenues, 2006-2011
- Table 16. WW Regions Market Shares (%), 2007 & 2011
- Table 17. US RNAi Market By Application Segment Revenues ($M), 2006-2011
- Table 18. Application Segment Market Shares (%), 2007 & 2011
- Table 19. RNAi Market By Major Disease Segments, Revenues ($M), 2006-2011
- Table 20. Major Disease Segment Market Shares (%), 2007 & 2011
- Table 21. RNAi Market By Product Segments, Revenues ($M), 2006-2011
- Table 22. Product Segment Market Shares (%), 2007 & 2011
- Table 23. RNAi R&D Unmet Needs - Selected Opportunity Matrix
- List of Illustrations
- Figure 1. Timeline for Key RNAi Technology Developments
- Figure 2. Central Theme of Modern Biology, DNA encodes for Proteins
- Figure 3. The RNAi Process with dsRNA, shRNA, siRNA and RISC
- Figure 4. RNAi R&D Market by Major Applications
- Figure 5. RNAi Related Patent Applications (US), 2002-1H2007
- Figure 6. New Drug Approval Timeline and Roadmap
- Figure 7. WW RNAi Market Size By Total Revenues ($M), 2006-2011
- Figure 8. WW RNAi Market By WW Regions and Revenues, 2006-2011
- Figure 9. WW RNAi Market By WW Regions and Shares, 2007 & 2011
- Figure 10. WW RNAi Market By Application Segment Revenues, 2006-2011
- Figure 11. RNAi Application Segment Market Shares (%), 2007 & 2011
- Figure 12. RNAi Market By Major Disease Segments, Revenues ($M), 2006-2011
- Figure 13. Major Disease Segment Market Shares (%), 2007 & 2011
- Figure 14. RNAi Market By Product Segments, Revenues ($M), 2006-2011
- Figure 15. Product Segment Market Shares (%), 2007 & 2011
- Figure 16. RNAi Future Direction Timeline to 2011
AbstractThis report assesses the RNA interference market for drug R&D. RNA interference (RNAi) has been hailed in the science media as the hottest technical breakthrough in bioscience in the last ten years. A 2006 Nobel Prize was awarded to the two scientists that discovered this important biological effect.
RNAi allows scientists to disrupt or silence the expression of a gene being studied. RNAi can also be used as a therapeutic agent. This field has quickly emerged as a fast growing young market. The report provides the WW outlook and market trends.
This must-have report discusses how an expanding number of companies have created a vibrant commercial market that has segmented into different areas of life science research and drug R&D. The market might be worth billions in a few years.
This study reviews the market landscape and analyzes the players. The market areas studied range from life science research products and services to therapeutics or drug delivery tools for RNAi agents.
The report discusses RNAi topics including dsRNA, shRNA, siRNA, ddRNA, miRNA, RNAi-as-drug, and targeted disease areas. This study analyzes RNAi deals including M&As, alliances and examples of patent considerations. For example, a number of big pharma companies are developing drugs with RNAi and have either licensed or partnered with RNAi R&D companies. One big pharma acquired a leading RNAi developer.
This report is designed for people that include marketers, business development, top executives, investors, VCs, consultants, R&D managers, entrepreneurs and etc. The report includes 39 detailed tables and figures that provide key data about items such as strategic alliances, M&As, market size, segments and so on.
Twenty company profiles provide the reader a snapshot of the companies' focus or activities. This PDF formatted report is searchable by using key words. Internet links help readers access companies' own web sites for further review.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
